Trial Profile

A Phase III Randomized Controlled Multi-centre Trial to Evaluate the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical Malaria

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 May 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2026.
02 Feb 2024 According to Novavax media release, data from this trial served as the basis for the World Health Organizations (WHO) recent prequalification of the R21/Matrix-M vaccine, paving the way for a global rollout that is expected to commence in mid-2024 by Serum Institute of India.
02 Feb 2024 According to Novavax media release, data from the study were presented in The Lancet.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com